Erchonia Corp. v. VibraGenix: Laser Therapy Patent Case Transferred in Washington District Court

Case Overview

A patent infringement action involving low-level laser therapy (LLLT) technology has moved swiftly through Washington’s Eastern District Court — filed and transferred on the same day. On July 28, 2025, Erchonia Corporation LLC initiated Case No. 2:25-cv-00273 against VibraGenix LLC, asserting infringement of two medical device patents tied to the commercially significant Emerald Laser platform. The court immediately transferred proceedings to Case No. 4:25-cv-5093-MKD before the Honorable Mary K. Dimke in Richland, Washington.

While the transfer itself carries no substantive ruling on infringement or validity, the speed and mechanics of this procedural development offer meaningful signals for patent attorneys monitoring LLLT patent litigation, IP professionals tracking Erchonia’s aggressive enforcement posture, and R&D teams operating in the non-invasive body contouring and therapeutic laser space. This case warrants close attention as it advances in its new venue.

The Parties

The Patents at Issue

Two utility patents form the basis of Erchonia’s infringement claims:

• • US7947067B2 — A foundational Erchonia patent covering low-level laser therapy methods and devices, likely encompassing specific wavelength, dosing, or treatment protocol claims relevant to aesthetic and therapeutic laser applications.
• • US9149650B2 — A subsequent patent in Erchonia’s LLLT portfolio, potentially directed to improvements in laser device configurations or treatment methodologies.

Both patents are issued U.S. utility patents. Practitioners can review full claim sets via the USPTO Patent Full-Text Database using the above patent numbers.

The Accused Product

The Emerald Laser is the product identified in Erchonia’s complaint as the accused infringing device. The Emerald Laser is a low-level laser system marketed for non-invasive fat reduction and body contouring. Its commercial positioning in the aesthetic wellness market — targeting clinics, med-spas, and wellness centers — makes it a direct competitive concern for Erchonia’s own laser product lines.

Legal Representation

Plaintiff’s Counsel: Mark P. Walters of Lowe Graham & Jones PLLC (Seattle, WA) represents Erchonia. Lowe Graham & Jones is a respected Pacific Northwest IP boutique with significant experience in patent prosecution and enforcement. No defendant counsel has appeared on record as of the transfer date.

Litigation Timeline & Procedural History

The case duration between filing and transfer was effectively zero days — a same-day administrative transfer rather than a contested venue motion. This procedural move reflects standard divisional reassignment within the Eastern District of Washington, directing the matter to Judge Mary K. Dimke in Richland. This is not a transfer under 28 U.S.C. § 1404(a) based on convenience arguments; rather, it reflects internal court docketing protocols for geographic or caseload allocation within the district.

The Eastern District of Washington encompasses both Spokane and Richland divisions. Filings in the Spokane division are sometimes redirected to Richland depending on case type, subject matter, or judicial assignment rules. For patent litigators, understanding these intra-district mechanics is essential when evaluating initial venue selection strategy in Washington state.

The case proceeds as a first-instance district court matter with all future substantive activity to occur under docket 4:25-cv-5093-MKD.

The Verdict & Legal Analysis

Outcome

No substantive verdict, ruling, or settlement has been reached. The case closed administratively at the original docket number solely due to the intra-district transfer. The infringement claims remain fully live under the reassigned case number before Judge Mary K. Dimke. No damages have been assessed, no injunctive relief has been granted or denied, and no invalidity rulings have been issued.

Procedural Transfer Analysis

The same-day transfer is significant for what it reveals about plaintiff’s filing strategy and court administration. Erchonia, represented by experienced IP counsel at Lowe Graham & Jones, filed in the Eastern District — a venue with a predictable docket, familiarity with complex civil litigation, and federal procedural infrastructure suited to patent disputes. The immediate redirection to the Richland division under Judge Dimke suggests this assignment was either anticipated or is a routine function of the district’s case management rules.

For litigators, this underscores a critical practice point: venue selection within a district matters as much as district selection itself. Patent plaintiffs must investigate divisional assignment practices, individual judge patent experience, and local rules before filing, particularly in districts with multiple active courthouses.

Legal Significance of the Asserted Patents

The two asserted patents — US7947067B2 and US9149650B2 — represent Erchonia’s strategic IP in LLLT. Key claim construction battlegrounds in future proceedings are likely to include:

• • Wavelength and emission parameters: LLLT patents frequently hinge on specific laser specifications; how broadly or narrowly the court construes these claim terms will be determinative.
• • Treatment methodology claims: Method claims in medical device patents require careful analysis of whether the accused product’s instructions or intended use bring it within claim scope.
• • Doctrine of equivalents: If the Emerald Laser’s specifications fall outside literal claim scope, Erchonia may pursue equivalents arguments, a legally demanding but strategically significant avenue.

Strategic Takeaways

For Patent Holders:
Erchonia’s filing demonstrates a proactive enforcement posture. Companies holding foundational LLLT patents should conduct periodic competitive landscape audits, identifying new market entrants whose products may implicate existing claim portfolios. Early filing before a competitor establishes significant market share is a well-recognized litigation strategy.

For Accused Infringers:
VibraGenix has not yet appeared through counsel. Any company facing patent infringement allegations — particularly in a fast-moving technology space like therapeutic lasers — should retain experienced patent litigation counsel immediately upon service of complaint. Early invalidity analysis of asserted patents, including prior art searches targeting the application priority dates of US7947067B2 and US9149650B2, is essential pre-litigation groundwork. Inter partes review (IPR) petitions at the USPTO represent a parallel invalidity challenge avenue worth evaluating.

For R&D Teams:
Developers working in low-level laser therapy, non-invasive body contouring, or photobiomodulation should conduct freedom-to-operate (FTO) analyses against Erchonia’s patent portfolio before commercializing new products. The Emerald Laser litigation signals that Erchonia is actively monitoring and enforcing its IP in this space.

Industry & Competitive Implications

The LLLT and non-invasive body contouring market has expanded substantially, with numerous devices entering the med-spa and aesthetic clinic segments. Erchonia’s enforcement of US7947067B2 and US9149650B2 against the Emerald Laser reflects a broader pattern of established LLLT patent holders defending market position against new entrants leveraging similar laser-based mechanisms.

For the broader therapeutic laser industry, this litigation signals continued IP friction as the category matures. Companies marketing low-level laser systems for fat reduction, pain management, or photobiomodulation should treat Erchonia’s portfolio as an active enforcement risk, not merely a prosecution reference.

Licensing considerations are also relevant. If the underlying claims are found valid and infringed in subsequent proceedings, the case could establish a licensing framework or damages benchmark applicable to other LLLT competitors. Conversely, a successful invalidity challenge by VibraGenix could open market space for multiple device manufacturers.

Related cases and Erchonia’s litigation history can be tracked through PACER and other patent litigation databases.